Levofolic (Levoleucovorin Disodium)

Levoleucovorin Disodium provides a reduced form of folate that bypasses the block created by antifolate drugs on dihydrofolate reductase. By entering cells directly, it restores the folate cycle needed for DNA synthesis, allowing healthy cells to recover while cancer cells remain targeted by the chemotherapy.

The dose of Levofolic is individualized and set by the prescribing physician based on the specific chemotherapy regimen, patient weight, renal function, and clinical response. Healthcare professionals determine the appropriate amount and infusion rate for each patient.

Safety data for Levofolic in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Levofolic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative is folinic acid (leucovorin calcium). Both are reduced folates used for rescue, but Levofolic (levoleucovorin disodium) is more soluble and formulated for intravenous injection, offering rapid plasma concentrations. Clinical efficacy is comparable, while formulation differences may influence handling and stability.

Levofolic must be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. If a temporary temperature excursion occurs, discard the product according to local regulations.

Levofolic is supplied as a sterile solution for injection and is administered intravenously. The infusion is typically given over a short period (e.g., 5–30 minutes) following high‑dose methotrexate or concurrently with antifolate chemotherapy, as directed by the treating oncologist.

Serious risks include anaphylactic reactions, severe hypotension, acute renal toxicity, cardiac arrhythmias, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely during and after infusion for any signs of these events, and immediate medical intervention should be initiated if they occur.

Levofolic is contraindicated in individuals with known hypersensitivity to levoleucovorin or any component of the formulation. Caution is advised for patients with severe renal impairment, uncontrolled hypertension, or a history of severe allergic reactions to folate products.